NKTRHealthcareMid-Cap

NEKTAR THERAPEUTICS Insider Trading Activity

Every SEC Form 4 insider transaction reported for NEKTAR THERAPEUTICS (NKTR), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are NKTR insiders buying or selling?

NEKTAR THERAPEUTICS insiders reported 2 open-market buys ($549.4K) and 212 sells ($91.9M) across 214 Form 4 filings — a net selling position of $91.3M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jul 2, 2026)

Total Form 4 filings
214
SEC EDGAR
Insider filers
18
Insider buys (2)
$549.4K
Insider sells (212)
$91.9M

Insider sentiment

Net selling

Net insider flow of $91.3M in net selling.

Recent NKTR insider transactions

DateInsiderRoleTypeSharesPriceValue
Jul 2, 2026Jonathan ZalevskyChief R&D OfficerSale5.7K$70.00$397.7K
Jun 18, 2026Howard W RobinPresident & CEOSale20.0K$60.75$1.2M
Jun 17, 2026Jonathan ZalevskyChief R&D OfficerSale5.5K$60.71$336.2K
May 21, 2026Jonathan ZalevskyChief R&D OfficerSale199$65.51$13.0K
May 21, 2026Howard W RobinPresident & CEOSale444$65.51$29.1K
Feb 21, 2026Jonathan ZalevskyChief R&D OfficerSale180$73.00$13.1K
Feb 21, 2026Howard W RobinPresident & CEOSale423$73.00$30.9K
Jan 23, 2026Jonathan ZalevskyChief R&D OfficerSale3.9K$35.67$137.9K
Nov 26, 2025Jonathan ZalevskyChief R&D OfficerSale1.2K$54.28$62.8K
Nov 26, 2025Mark Andrew WilsonChief Legal OfficerSale630$54.28$34.2K
Nov 26, 2025Howard W RobinPresident & CEOSale2.2K$54.28$119.8K
Sep 12, 2025Howard W RobinPresident & CEOSale6.7K$46.69$311.2K
Sep 9, 2025Jonathan ZalevskyChief R&D OfficerSale1.7K$33.52$57.7K
Sep 9, 2025Howard W RobinPresident & CEOSale11.8K$36.42$431.0K
Sep 5, 2025Jonathan ZalevskyChief R&D OfficerSale485$30.10$14.6K
Sep 5, 2025Howard W RobinPresident & CEOSale1.5K$30.16$45.2K
Aug 22, 2025Jonathan ZalevskyChief R&D OfficerSale725$26.59$19.3K
Aug 22, 2025Mark Andrew WilsonChief Legal OfficerSale676$26.59$18.0K
Aug 22, 2025Howard W RobinPresident & CEOSale1.6K$26.59$41.8K
May 22, 2025Jonathan ZalevskyChief R&D OfficerSale10.7K$0.67$7.2K
May 22, 2025Mark Andrew WilsonChief Legal OfficerSale10.0K$0.67$6.7K
May 22, 2025Howard W RobinPresident & CEOSale23.2K$0.67$15.5K
Feb 21, 2025Jonathan ZalevskyChief R&D OfficerSale10.3K$1.01$10.4K
Feb 21, 2025Mark Andrew WilsonChief Legal OfficerSale11.0K$1.01$11.2K
Feb 21, 2025Howard W RobinPresident & CEOSale23.8K$1.01$24.0K

Showing the 25 most recent of 214 Form 4 filings for NEKTAR THERAPEUTICS.

Most active NKTR insiders

  • Howard W Robin43 filings
  • Jonathan Zalevsky35 filings
  • Gil M Labrucherie25 filings
  • Mark Andrew Wilson25 filings
  • Jillian B. Thomsen22 filings

Ask anything about NKTR insider activity

Use Trabud's AI agent to query NEKTAR THERAPEUTICS's Form 4 history in plain English — "Show me NKTR CEO purchases this year" or compare it against any other ticker.

Open the AI agent

NKTR insider trading FAQ

Are NEKTAR THERAPEUTICS insiders buying or selling?

Across 214 SEC Form 4 filings, NEKTAR THERAPEUTICS (NKTR) insiders reported 2 open-market purchases totaling $549.4K and 212 sales totaling $91.9M. That is a net selling position of $91.3M.

How many insiders trade NKTR stock?

18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for NEKTAR THERAPEUTICS. The most recent filing was accepted on Jul 2, 2026.

Where does Trabud get NKTR insider trading data?

All NKTR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content